Competition for Anavex by TauRx? The question I have is: How much of a competitor? Thus, I put all of the below together.
One theory of how AVXL 2-73 works is that it stops or limits nitration and oxidative stress. There is evidence that suggests that oxidative damage to proteins and other macromolecules is a feature of the pathology of Alzheimer’s disease. See: Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease - The Journal of Neuroscience www.jneurosci.org › content.
''Increasing evidence suggests that oxidative damage to proteins and other macromolecules is a salient feature of the pathology of Alzheimer’s disease. Establishing the source of oxidants is key to understanding what role they play in the pathogenesis of Alzheimer’s disease, and one way to examine this issue is to determine which oxidants are involved in damage.
In this study, we examine whether peroxynitrite, a powerful oxidant produced from the reaction of superoxide with nitric oxide, is involved in Alzheimer’s disease. Peroxynitrite is a source of hydroxyl radical-like reactivity, and it directly oxidizes proteins and other macromolecules with resultant carbonyl formation from side-chain and peptide-bond cleavage. Although carbonyl formation is a major oxidative modification induced by peroxynitrite, nitration of tyrosine residues is an indicator of peroxynitrite involvement. In brain tissue from cases of Alzheimer’s disease, we found increased protein nitration in neurons, including but certainly not restricted to those containing neurofibrillary tangles (NFTs). Conversely, nitrotyrosine was undetectable in the cerebral cortex of age-matched control brains. This distribution is essentially identical to that of free carbonyls.
These findings provide strong evidence that peroxynitrite is involved in oxidative damage of Alzheimer’s disease. Moreover, the widespread occurrence of nitrotyrosine in neurons suggests that oxidative damage is not restricted to long-lived polymers such as NFTs, but instead reflects a generalized oxidative stress that is important in disease pathogenesis."
See also NEW YORK, NY – February 25, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) is encouraged by the findings of a research report in the current issue of peer-reviewed scientific journal Frontiers in Cellular Neuroscience. Among its conclusions, the report reveals that ANAVEX 2-73 prevents mitochondrial dysfunction and blocks resulting oxidative stress and apoptosis (cell death) in a nontransgenic mouse model of Alzheimer’s disease (AD). Mitochondrial damages have been consistently reported as an early cause of AD and appear before amyloid-beta plaques and memory decline in Alzheimer’s patients and transgenic mice. Thus, by preserving mitochondrial functionality and reducing other key AD hallmarks, ANAVEX 2-73 has the potential to prevent, stop, slow or reverse the disease, in addition to treating its symptoms.
TauRx is a competitor of Anavex. TauRx may prevent tau aggregation, and as pointed out by Ipulator: "Many of TRx023's supposed beneficial effects, including neuroprotection via mitochondrial antioxidant properties...." makes for competition for Anavex.
Orveko had this to say about TauRx:
''orveko_inc Sunday, 07/05/15 01:57:49 PM
Re: Rwingsguy post# 5618
Post # of 65440
TauRx/LMTX and Anavex/2-73 have an interesting relationship.
LMTX is basically just methylene blue. One of Anavex's most advanced patent applications (14/205637) covers a combination therapy of Anavex 2-73 + methylene blue for the treatment of cancer and neuropathic pain.
If LMTX and 2-73 prove to be independently successful for the treatment of Alzheimer's, perhaps we may see the Anavex 2-73 + methylene blue combo therapy expand to cover the treatment of Alzheimer's as well. Who knows - maybe we will even see Anavex PLUS+ (2-73 + donepezil + methylene blue).
2-73 could turn into quite the pipeline all by itself."
Methylene Blue has apparently been around for a long time. Perhaps Orveko may be able to comment about whether Methylene Blue or its molecule by itself is perhaps not subject to patent, and the significance of the patent that Anavex has on the combination of Methylene Blue and AVXL 2-73 for cancer and neuropathic pain , the patent that Anavex has on AVXL 2-73, and whether Anavex needs a patent on the combination of Methylene Blue and AVXL 2-73 for the treatment of AD?
